再生障碍性贫血患者免疫调节剂治疗前后TNF和IL—2水平变化及意义

为了探讨再生障碍性贫血（ＡＡ）的免疫发病机理及抗Ｔ淋巴细胞单克隆抗体（ＭｃＡｂ－Ｔ）的免疫调节治疗作用，采用放射免疫法检测３０例ＡＡ患者ＭｃＡｂ－Ｔ治疗前后血清肿瘤坏死因子（ＴＮＦ）和白细胞介素－２（ＩＬ－２）水平及其中１０例ＡＡ外周血核细胞（ＰＢＭＮＣ）体外诱生ＴＮＦ和ＩＬ－２水平的变化。结果表明，治疗前ＡＡ患者血清ＴＮＦ水平显著曾高（Ｐ〈０．０１），ＰＢＭＮＣ诱生的ＴＮＦ和ＩＬ－２水平均明显高

CHANGES OF TNF AND IL-2 LEVELS IN APLASTIC ANEMIA PATIENTS AFTER TREATMENT WITH IMMUNOMODULATOR

The aim of this study was to investigate the immune pathogeny of aplastic anemia (AA) and the effect of immunoregulatory therapy with monoclonal anti-human T lymphocyteantibody(McAb-T).The levels of tumor necrosis factor(TNF) and interleukin-2 (IL-2) in serum of 30 patients as well as in culture supernatant of peripheral blood mononuclear cells (PBMNC) in the presence of phytohemagglu-tinin(PHA)of 10 of these 30 patients with AA were analysed with radio-immuno-assay methods before and after McAb-T therapy. The results showed that before therapy the levels of TNF, both in serum and in culture supernatant of PBMNC were significantly higher than those in normal controls (p<0.01); IL-2 levels were significantly higher in culture supernatant of PBMNC (p<0.01)but not in serum. After therapy all those levels were decreased and little difference from normal control remained (p>0.05). The abnormal product ion of hematopoietic regulation cytokines TNF and IL-2 could play an important role in the progression of AA patients. McAb-T could play a specific immunoregulatory role and abolish the inhibitory action, directly or indirectly, on hematopoiesis by T lymphocytes and relative cytokines.